FDA approves Celgene's Otezla for psoriasis

FDA approved an sNDA from Celgene Corp. (NASDAQ:CELG) for Otezla apremilast to treat moderate to severe plaque psoriasis. Celgene said the oral drug is the only approved phosphodiesterase-4 (PDE-4) inhibitor for the indication. In March, FDA approved Otezla to treat adults with active psoriatic arthritis.

Otezla is under review in Canada and Europe for psoriatic arthritis and psoriasis. ...